Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Design Therapeutics, Inc.’s reported figures.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026. Open the filing →
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
FAQ
- What is Design Therapeutics, Inc.'s EBIT?
- Design Therapeutics, Inc. (DSGN) reported EBIT of -$19.71M in Q1 2026.
- How has Design Therapeutics, Inc.'s EBIT changed year-over-year?
- Design Therapeutics, Inc.'s EBIT increased by 3.5% year-over-year, from -$20.42M to -$19.71M.
- What is the long-term trend for Design Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s EBIT has grown at a 22.0% compound annual growth rate (CAGR), from -$35.83M to -$79.47M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Design Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude